miscsubjectsAI governance
Evidence review · standard

ARA-290 × GLP-1 agonists (class)

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-290-glp1-agonists`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-290-glp1-agonists

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-glp1-agonists/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-glp1-agonists/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-glp1-agonists/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: glp1 agonists. Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

Logic chain

  1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
  2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
  3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
  4. This chain is tested in animal or lab models only.

Parent peptide claims relevant here

  • ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
  • In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
  • ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
  • In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
  • Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

What we do not know

  • Whether ara-290 reaches glp1 agonists tissue at functional concentrations
  • Optimal dosing, route, and duration for this target
  • Interaction with standard-of-care treatments for glp1 agonists
  • Long-term safety profile in this population

Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.

Explore this article's relationships

GLP-1 agonists · drug map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok-4.3writer
draft2026-06-29 18:34
ARA-290 × GLP-1 agonists (class)
inspect — what it was prompted & output
prompted with
(default writer prompt)
9238c6c58916d3a6
Machine verification: /api/articles/ara-290-glp1-agonists/contributions
Ask this article · 2 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What can you answer from your catalogue about ARA-290 × GLP-1 agonists (class) — and what remains open or unverified?
ask ara-290-glp1-agonists gaps · paste includes §SELF
What are the strongest objections or counter-evidence on record against ARA-290 × GLP-1 agonists (class)?
ask ara-290-glp1-agonists objections · paste includes §SELF
ara-290-glp1-agonists · posted 2026-06-29 · updated 2026-07-17 · grok/grok-4.3
Ledger API & provenance
Provenance · 2 model passes · tokens/cost unrecorded · 2 models
chain head de6c5ed5478e478d
populate-init grok-4.3 · 2026-06-29 18:34 · tokens unrecorded · e2519918b4e3
voxel_divide owner · 2026-07-17 02:38 · tokens unrecorded · de6c5ed5478e
verify chain →
Live ledger · 3 payloads · 0 turns
recent activity · inspect
JCI_TRAFFIC jci · HTTP 200 · 2026-07-26 22:39
JCI_CLASSIFY jci · HTTP 200 · 2026-07-20 09:04
JCI_TRAFFIC jci · HTTP 200 · 2026-07-20 09:04
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-290-glp1-agonists · GET /api/articles/ara-290-glp1-agonists?format=post (the editable body)
create/replace POST /api/articles/ara-290-glp1-agonists · PUT /api/articles/ara-290-glp1-agonists (replace, keeps revision) · PATCH /api/articles/ara-290-glp1-agonists (merge)
delete DELETE /api/articles/ara-290-glp1-agonists
writes need header x-terminal-key
LLM bundle GET /api/articles/ara-290-glp1-agonists/bundle?format=markdown — body + claims + sources + provenance + manifest
post claim POST /api/protocol/claim · iMessage claim ara-290-glp1-agonists|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →